Marousa Kouvela

Dr. Marousa Kouvela

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2010 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
DTDimitris Toumpanakis
Dimitris Toumpanakis
George KastisGeorge Kastis
George Kastis
PZPanagiotis Zacharatos
Panagiotis Zacharatos
ISIoanna Sigala
Ioanna Sigala
TMTatiana Michailidou
Tatiana Michailidou
TVTheodoros Vassilakopoulos
Theodoros Vassilakopoulos
Rationale: Resistive breathing is associated with large negative intrathoracic pressures. Increased mechanical stress induces high-permeability pulmonary edema and lung inflammation. Objectives: To determine the effects of resistive breathing on the healthy lung. Methods: Anesthetized rats breathed through a two-way nonrebreathing valve. The inspiratory line was connected to a resistance setting peak inspiratory tracheal pressure at 50% of maximum (inspiratory resistive breathing), while 100% oxygen was supplied to prevent hypoxemia. Quietly breathing animals (100% oxygen) served as controls. Lung injury was evaluated after 3 and 6 hours of resistive breathing. Measurements and Main Results: After both 3 and 6 hours of resistive breathing, lung permeability was increased, as assessed by 99mTc-diethylenetriaminepentaacetic acid scintigraphy and Evans blue dye extravasation. Tissue elasticity, measured on the basis of static pressure–volume curves and by the low-frequency forced oscillation technique, was also increased. After both 3 and 6 hours of resistive breathing, gravimetric measurements revealed the presence of pulmonary edema and analysis of bronchoalveolar lavage showed increased total protein content, whereas the total cell count was elevated only after 6 hours of resistive breathing. Cytokine levels were assessed in bronchoalveolar lavage fluid and lung tissue by ELISA and were increased after 6 hours compared with controls. Western blot analysis showed early activation of Src kinase via phosphorylation (at 30 min), and Erk1/2 and IκBα (nuclear factor-κB inhibitor) were phosphorylated at 3 and 6 hours. Pathology revealed the presence of lung injury after resistive breathing. Conclusions: Resistive breathing induces acute lung injury and inflammation.

26 May 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
DSDimitra Theodore Stefanou
Dimitra Theodore Stefanou
Marousa KouvelaMarousa Kouvela
Marousa Kouvela
DSDimitrios Stellas
Dimitrios Stellas
KVKonstantinos Voutetakis
Konstantinos Voutetakis
OPOlga Papadodima
Olga Papadodima
VSVassilis Souliotis
Vassilis Souliotis
The deregulated DNA damage response (DDR) network is associated with the onset and progression of cancer. Herein, we searched for DDR defects in peripheral blood mononuclear cells (PBMCs) from lung cancer patients, and we evaluated factors leading to the augmented formation of DNA damage and/or its delayed/decreased removal. In PBMCs from 20 lung cancer patients at diagnosis and 20 healthy controls (HC), we analyzed oxidative stress and DDR-related parameters, including critical DNA repair mechanisms and apoptosis rates. Cancer patients showed higher levels of endogenous DNA damage than HC (p < 0.001), indicating accumulation of DNA damage in the absence of known exogenous genotoxic insults. Higher levels of oxidative stress and apurinic/apyrimidinic sites were observed in patients rather than HC (all p < 0.001), suggesting that increased endogenous DNA damage may emerge, at least in part, from these intracellular factors. Lower nucleotide excision repair and double-strand break repair capacities were found in patients rather than HC (all p < 0.001), suggesting that the accumulation of DNA damage can also be mediated by defective DNA repair mechanisms. Interestingly, reduced apoptosis rates were obtained in cancer patients compared with HC (p < 0.001). Consequently, the expression of critical DDR-associated genes was found deregulated in cancer patients. Together, oxidative stress and DDR-related aberrations contribute to the accumulation of endogenous DNA damage in PBMCs from lung cancer patients and can potentially be exploited as novel therapeutic targets and non-invasive biomarkers.

30 September 2019 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
PGPeter Georgakopoulos
Peter Georgakopoulos
MKMichael Kyriakidis
Michael Kyriakidis
APAnastasia Perpinia
Anastasia Perpinia
AKApostolos Karavidas
Apostolos Karavidas
SZStelios Zimeras
Stelios Zimeras
ACAndriani Charpidou
Andriani Charpidou
Background/Aim: Anthracyclines, such as doxorubicin, though widely used in anticancer therapy, they are associated with cardiotoxic side-effects. The aim of this trial was to investigate long-term follow-up cardiotoxicity findings in patients treated with doxorubicin and concomitant metoprolol or enalapril 10 years earlier. Patients and Methods: Overall, 147 patients were randomized into the treatment arms. A total of 125 patients treated with doxorubicin without evidence of heart disease at the start of chemotherapy were analyzed. They were followed-up for up to 10 years after treatment start. Results and Conclusion: A total of 47 patients completed the follow-up and 21 patients died, none due to cardiotoxicity events. Clinical signs of heart failure were not seen in any patients and no statistically significant differences between baseline and 10-year findings were seen for echocardiographic variables. No evidence of long-term cardiotoxicity was seen and nor metoprolol or enalapril offered an additional benefit.

13 November 2025 in Medicines
Verified
Journal Article
Open access
PDF file
PKParaskevi Keramida
Paraskevi Keramida
NSNIKOLAOS SYRIGOS
NIKOLAOS SYRIGOS
Marousa KouvelaMarousa Kouvela
Marousa Kouvela
GPGaryfallia Poulakou
Garyfallia Poulakou
ACAndriani Charpidou
Andriani Charpidou
OFOraianthi Fiste
Oraianthi Fiste
Drug repurposing is the process of discovering new therapeutic indications for already existing drugs. By using already approved molecules with known safety profiles, this approach reduces the time, costs, and failure rates associated with traditional drug development, accelerating the availability of new treatments to patients. Artificial Intelligence (AI) plays a crucial role in drug repurposing by exploiting various computational techniques to analyze and process big datasets of biological and medical information, predict similarities between biomolecules, and identify disease mechanisms. The purpose of this review is to explore the role of AI tools in drug repurposing and underline their applications across various medical domains, mainly in oncology, neurodegenerative disorders, and rare diseases. However, several challenges remain to be addressed. These include the need for a deeper understanding of molecular mechanisms, ethical concerns, regulatory requirements, and issues related to data quality and interpretability. Overall, AI-driven drug repurposing is an innovative and promising field that can transform medical research and drug development, covering unmet medical needs efficiently and cost-effectively.

1 October 2020 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
APAndriana I Papaioannou
Andriana I Papaioannou
SLStelios Loukides
Stelios Loukides
PBPetros Bakakos
Petros Bakakos
EKEpameinondas N Kosmas
Epameinondas N Kosmas
NRNikoletta K. Rovina
Nikoletta K. Rovina
NTNikos Tzanakis
Nikos Tzanakis
Pharmacological medications used for the treatment of COPD patients have increased significantly. Long-acting bronchodilators have been recognized as the mainstay of the treatment of stable COPD, while ICS are usually added in patients with COPD who experience exacerbations, despite bronchodilator treatment. In the latest years, several studies have been published showing the beneficial effect of adding ICS on dual bronchodilation in patients suffering from more severe disease comparing triple therapy with several therapeutic regiments including dual bronchodilation and providing a message that this triple therapy might be more appropriate for COPD patients. However, not all COPD patients have a desirable response to ICS treatment while long-term ICS use in COPD is associated with several side effects. In this report, we aimed to provide a review of the current knowledge on the importance of dual bronchodilation on COPD patients and to compare its use with triple therapy, by covering a wide spectrum of topics. Finally, we propose an algorithm on performing treatment step up from dual bronchodilation to triple therapy and step down from triple to double bronchodilation considering the current evidence.

8 April 2024 in Cancers
Verified
Journal Article
Open access
PDF file
Marousa KouvelaMarousa Kouvela
Marousa Kouvela
MLMaria Effrosyni Livanou
Maria Effrosyni Livanou
DSDimitra Theodore Stefanou
Dimitra Theodore Stefanou
IVIoannis Vathiotis
Ioannis Vathiotis
FSFotini Sarropoulou
Fotini Sarropoulou
NSNIKOLAOS SYRIGOS
NIKOLAOS SYRIGOS
Background: The aim of this study was to record and assess the efficacy and safety ofthromboprophylaxis with an intermediate dose of Tinzaparin in lung cancer patients with high thrombotic risk. Methods: This was a non-interventional, single-arm, prospective cohort study of lung cancer patients who received thromboprophylaxis with Tinzaparin 10.000 Anti-Xa IU in 0.5 mL, OD, used in current clinical practice. Enrolled ambulatory patients signed informed consent. Anti-Xa levels were tested. Results: In total, 140 patients were included in the study, of which 81.4% were males. The histology of the tumor was mainly adenocarcinoma. Lung cancer patients with high thrombotic risk based on tumor, patient, treatment, and laboratory-related factors were enrolled. Only one patient experienced a thrombotic event (0.7%), and 10 patients had bleeding events (7.1%), including only one major event. Anti-Xa levels measured at 10 days and 3 months did not differ significantly between patients who developed hemorrhagic events and those who did not (p = 0.26 and p = 0.32, respectively). Conclusion: Thromboprophylaxis with an intermediate Tinzaparin dose in high thrombotic-risk lung cancer patients is a safe and effective choice for the prevention of VTE.